ImmunityBio Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IBRX?
Source: Newsfilter
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, covering the period from January 19, 2026, to March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva medication, resulting in public statements that were materially misleading throughout the class period, potentially causing significant losses for investors.
- Investor Participation: Affected shareholders are encouraged to contact DJS Law Group to participate in the lawsuit, with the understanding that appointment as lead plaintiff is not required to partake in any recovery, thus providing an opportunity for investors to recover their losses.
- Law Group Expertise: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions, corporate governance litigation, and domestic/international M&A appraisals, committed to delivering high-value legal services to its clients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.380
Low
5.00
Averages
7.33
High
9.00
Current: 7.380
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Bladder Cancer Drug Trial Confirms Statistical Power
- Trial Statistical Power Confirmed: The Independent Data Monitoring Committee (IDMC) confirmed that ImmunityBio's pivotal randomized trial for Anktiva is adequately powered with the current 366 participants, ensuring the study's effectiveness in detecting clinically meaningful differences in complete response rates.
- Clinical Trial Progress: The QUILT-2.005 trial evaluates Anktiva in combination with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer, showing promising results from earlier phases with prolonged complete remission durations, enhancing confidence for subsequent research.
- FDA Regulatory Dynamics: The U.S. FDA reviewed direct-to-consumer advertising for Anktiva, deeming it misleading and unsupported in claims of curing or preventing cancer, highlighting the importance of compliance in promotional materials.
- Analyst Ratings and Targets: ImmunityBio's stock carries a Buy rating with an average price target of $12.57, while D. Boral Capital maintains a target of $23.00, reflecting market confidence in the company's future potential.
See More
Faruqi & Faruqi Investigates Potential Claims Against ImmunityBio
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, aiming to protect investor rights.
- Investor Contact Information: The firm encourages investors who suffered losses during the specified period to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Reminder: Faruq & Faruqi reminds investors that May 26, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against ImmunityBio, emphasizing the importance of timely action.
- Securities Law Expertise: As a leading national securities law firm, Faruq & Faruqi focuses on protecting investor rights and investigating potential securities fraud, demonstrating its expertise in maintaining market integrity.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, covering the period from January 19, 2026, to March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva medication, resulting in public statements that were materially misleading throughout the class period, potentially causing significant losses for investors.
- Investor Participation: Affected shareholders are encouraged to contact DJS Law Group to participate in the lawsuit, with the understanding that appointment as lead plaintiff is not required to partake in any recovery, thus providing an opportunity for investors to recover their losses.
- Law Group Expertise: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions, corporate governance litigation, and domestic/international M&A appraisals, committed to delivering high-value legal services to its clients.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- FDA Warning Letter: The FDA issued a warning to ImmunityBio regarding misleading efficacy claims made by its chairman, Dr. Soon-Shiong, about Anktiva, resulting in a 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Initiated: Hagens Berman has launched a class action lawsuit on behalf of investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws and urging affected investors to submit their losses to support the investigation.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated there is no evidence supporting such claims and that promotional materials failed to disclose Anktiva's full FDA-approved indications, raising public health concerns.
- Investor Alert: Hagens Berman advises investors who suffered significant losses in ImmunityBio or possess information that could assist the investigation to contact the firm, ensuring their rights are protected in potential recovery efforts.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of ImmunityBio securities purchasers from January 19 to March 24, 2026, indicating significant legal risks that could impact the company's stock price and investor confidence.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, a no-risk arrangement that could attract more affected investors and enhance the lawsuit's overall impact.
- False Statement Allegations: The lawsuit alleges that ImmunityBio executives made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, which, if proven true, could severely damage the company's reputation and future business prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, can seek lead plaintiff status by May 26, 2026, indicating significant investor concern over potential legal risks facing the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements regarding the efficacy of its lead biologic product, Anktiva, which could lead to investor misjudgment about the company's future prospects.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter stating that ImmunityBio's advertising misbranded Anktiva, resulting in a 21% drop in stock price, reflecting the direct impact of regulatory risks on the company's market valuation.
- Law Firm's Strength: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strong capability and influence in handling similar cases.
See More
ImmunityBio's Bladder Cancer Drug Trial Confirms Statistical Power
- Trial Statistical Power Confirmed: The Independent Data Monitoring Committee (IDMC) confirmed that ImmunityBio's pivotal randomized trial for Anktiva is adequately powered with the current 366 participants, ensuring the study's effectiveness in detecting clinically meaningful differences in complete response rates.
- Clinical Trial Progress: The QUILT-2.005 trial evaluates Anktiva in combination with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer, showing promising results from earlier phases with prolonged complete remission durations, enhancing confidence for subsequent research.
- FDA Regulatory Dynamics: The U.S. FDA reviewed direct-to-consumer advertising for Anktiva, deeming it misleading and unsupported in claims of curing or preventing cancer, highlighting the importance of compliance in promotional materials.
- Analyst Ratings and Targets: ImmunityBio's stock carries a Buy rating with an average price target of $12.57, while D. Boral Capital maintains a target of $23.00, reflecting market confidence in the company's future potential.
See More
Faruqi & Faruqi Investigates Potential Claims Against ImmunityBio
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, aiming to protect investor rights.
- Investor Contact Information: The firm encourages investors who suffered losses during the specified period to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options.
- Class Action Reminder: Faruq & Faruqi reminds investors that May 26, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against ImmunityBio, emphasizing the importance of timely action.
- Securities Law Expertise: As a leading national securities law firm, Faruq & Faruqi focuses on protecting investor rights and investigating potential securities fraud, demonstrating its expertise in maintaining market integrity.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, covering the period from January 19, 2026, to March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva medication, resulting in public statements that were materially misleading throughout the class period, potentially causing significant losses for investors.
- Investor Participation: Affected shareholders are encouraged to contact DJS Law Group to participate in the lawsuit, with the understanding that appointment as lead plaintiff is not required to partake in any recovery, thus providing an opportunity for investors to recover their losses.
- Law Group Expertise: DJS Law Group focuses on enhancing investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions, corporate governance litigation, and domestic/international M&A appraisals, committed to delivering high-value legal services to its clients.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- FDA Warning Letter: The FDA issued a warning to ImmunityBio regarding misleading efficacy claims made by its chairman, Dr. Soon-Shiong, about Anktiva, resulting in a 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Initiated: Hagens Berman has launched a class action lawsuit on behalf of investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws and urging affected investors to submit their losses to support the investigation.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated there is no evidence supporting such claims and that promotional materials failed to disclose Anktiva's full FDA-approved indications, raising public health concerns.
- Investor Alert: Hagens Berman advises investors who suffered significant losses in ImmunityBio or possess information that could assist the investigation to contact the firm, ensuring their rights are protected in potential recovery efforts.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of ImmunityBio securities purchasers from January 19 to March 24, 2026, indicating significant legal risks that could impact the company's stock price and investor confidence.
- Compensation Structure: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket costs, a no-risk arrangement that could attract more affected investors and enhance the lawsuit's overall impact.
- False Statement Allegations: The lawsuit alleges that ImmunityBio executives made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, which, if proven true, could severely damage the company's reputation and future business prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, can seek lead plaintiff status by May 26, 2026, indicating significant investor concern over potential legal risks facing the company.
- False Statement Allegations: The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements regarding the efficacy of its lead biologic product, Anktiva, which could lead to investor misjudgment about the company's future prospects.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter stating that ImmunityBio's advertising misbranded Anktiva, resulting in a 21% drop in stock price, reflecting the direct impact of regulatory risks on the company's market valuation.
- Law Firm's Strength: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strong capability and influence in handling similar cases.
See More
